CCM
SAGE

Camber Capital Management’s Sage Therapeutics SAGE Stock Holding History

Camber Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-700,000
Closed -$26.7M – 44
2022
Q4 		$26.7M Buy
+700,000
New +$26.7M 0.92% 24
2020
Q3 		– Sell
-525,000
Closed -$21.8M – 38
2020
Q2 		$21.8M Buy
+525,000
New +$19.1M 1.25% 22

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Camber Capital Management's SAGE Position: Q1 2023 in Review

Camber Capital Management sold out of Sage Therapeutics (SAGE) in Q1 2023, closing a stake of 700,000 shares — an estimated $26.7M sold.

Camber Capital Management first reported a position in SAGE in Q2 2020 and held it in 2 quarters. The position peaked at $26.7M in Q4 2022. 213 funds tracked by Wall St. Rank hold SAGE as of Q1 2023.

  • Camber Capital Management reported no remaining Sage Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Camber Capital Management sold 700,000 Sage Therapeutics shares in Q1 2023, an estimated $26.7M.
  • Camber Capital Management first reported a position in Sage Therapeutics in Q2 2020 and held it in 2 quarters.
  • Camber Capital Management's Sage Therapeutics position peaked at $26.7M in Q4 2022.
  • 213 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2023.

Based on Camber Capital Management's 13F filing for Q1 2023, filed 15 May 2023.